Related Experiment Video

Updated: May 9, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Diabetes: glycaemic control in type 2 (drug treatments)

Kees J Gorter1, Floris Alexander van de Laar, Paul G H Janssen

  • 1University Medical Centre, Utrecht, The Netherlands.

BMJ Clinical Evidence
|July 19, 2013
PubMed
Abstract

Insights

This review examines blood-glucose-lowering medications for type 2 diabetes, evaluating the effectiveness and safety of various drug classes like metformin and insulins.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Diabetes mellitus is a progressive glucose metabolism disorder affecting 5% of adults globally.
  • Type 2 diabetes is linked to metabolic syndrome, increasing cardiovascular disease risk.
  • Inadequate treatment leads to rising blood glucose and potential microvascular/macrovascular complications.

Purpose of the Study:

  • To systematically review the effects of blood-glucose-lowering medications in adults with type 2 diabetes.
  • To assess the effectiveness and safety of various pharmacological interventions.
  • To inform clinical decision-making regarding diabetes management.

Main Methods:

  • Systematic review of 194 studies (reviews, RCTs, observational studies) up to February 2010.
  • Searched major databases including Medline, Embase, and The Cochrane Library.
  • Incorporated safety alerts from regulatory agencies like the FDA and MHRA.

Main Results:

  • Evaluated a wide range of glucose-lowering interventions.
  • Included alpha-glucosidase inhibitors (AGIs), DPP-4 inhibitors, GLP-1 analogues, insulins, meglitinides, metformin, sulfonylureas, and thiazolidinediones.
  • Assessed combination treatments (single, double, triple).

Conclusions:

  • Presents comprehensive information on the effectiveness of various diabetes medications.
  • Details the safety profiles of different blood-glucose-lowering drug classes.
  • Provides evidence for the management of type 2 diabetes through pharmacological interventions.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...